This underlines the broad applicability of the approach of targeting a common SNP, as well as for other (cardiac) diseases where no evidence-based treatments currently exist, such as genetic cardiomyopathies caused by LMNA or RBM20 mutations [49,50]. The gene discussed is LMNA; the disease is heart disorder.